Android app Apple app link

Summit Therapeutics (SMMT) Releases Financial Results and Updates on Operational Progress for Q3 2025

By Yahoo! Finance   |   1 month ago
Summit Therapeutics (SMMT) Releases Financial Results and Updates on Operational Progress for Q3 2025

Summit Therapeutics Inc. (NASDAQ:SMMT) is set for exponential growth in 2026 with plans to submit a Biologics License Application and start a Phase III clinical trial. Analysts maintain a "Buy" rating with a price target of $30.00.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.